Shield Therapeutics (Shield), an independent pharmaceutical company focused on the development of specialist hospital pharmaceuticals, today announces the online publication of the manuscript of the AEGIS Feraccru (ST10, ferric maltol) Phase 3 pivotal study in the latest edition of the Inflammatory Bowel Disease Journal, the official journal of the Crohn’s and Colitis Foundation of America.
Dr Julian Howell, Group Medical Director and VP Drug Development, commented:
“This peer-reviewed manuscript is an excellent portrayal of the potential, the features and the benefits of Feraccru and we look forward to further developing this important asset for the benefit of patients who cannot tolerate oral ferrous iron and so have to rely on the higher risk option of invasive and resource-consuming intravenous iron administration.”
This announcement follows the recent news that the Marketing Authorisation Application (MAA) for Feraccru, a novel orally-delivered form of ferric iron, has been accepted for review by the European Medicines Agency (EMA). Shield is seeking marketing authorisation of Feraccru for the treatment of iron deficiency anaemia (IDA), initially in patients with inflammatory bowel disease (IBD) and those intolerant of oral ferrous therapies, thereby providing an effective alternative to those patients whose only current option is intravenous iron therapy.
– Ends –
Members of Shield’s management team will be attending the upcoming JP Morgan Healthcare Conference in San Francisco from the 12th to 14th of January.
For more information about Shield Therapeutics, please contact:
Carl Sterritt, Chief Executive Officer, Tel +44 (0)20 7186 0360
Consilium Strategic Communications,
Mary-Jane Elliott / Lindsey Neville, Tel +44 (0)203 709 5700, Email: firstname.lastname@example.org
About Shield Therapeutics
Shield Therapeutics (www.shieldtx.com) is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield has successfully completed a pivotal Phase 3 programme of its lead asset, Feraccru, for the treatment of IDA associated with inflammatory bowel disease and is soon to commence a Phase 3 study of Feraccru for the treatment of IDA in patients with chronic kidney disease. Shield Therapeutics is also developing a novel iron-based phosphate binder, PT20, for the treatment of hyperphosphataemia related to dialysis-dependent or dialysis-independent chronic kidney disease. PT20 is currently completing a first pivotal trial.